Mibg (I123) Curium Netherlands

Iobenguane I-123, the active ingredient in Mibg (I123) Curium Netherlands, is a diagnostic radiopharmaceutical presented as an injectable solution for intravenous use. It is employed to visualize norepinephrine transporter activity in adrenergic tissues, supporting the detection and staging of neuroblastoma, pheochromocytoma, paraganglioma, and assessment of cardiac sympathetic innervation.

GNH USA supplies Mibg (I123) Curium Netherlands as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, nuclear medicine departments and clinics worldwide.

Mibg (I123) Curium Netherlands is used in diagnostic imaging of conditions that involve adrenergic tissue activity.

Neuroblastoma: enables precise tumor localization and staging. Pheochromocytoma: facilitates detection of catecholamine‑producing adrenal tumors. Paraganglioma: provides imaging of extra‑adrenal sympathetic tumors. Cardiac sympathetic innervation assessment: evaluates sympathetic nerve function in heart disease.

Mibg (I123) Curium Netherlands may cause a range of reactions after injection.

Common Side Effects: - Nausea or mild vomiting. - Transient flushing or warmth sensation. - Injection‑site pain or bruising. - Headache. - Mild hypotension. - Mild allergic skin reaction (rash or itching).

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction. - Marked hypotension requiring intervention. - Radiation‑induced skin injury at the injection site. - Thyroid dysfunction due to iodine exposure. - Severe cardiac arrhythmia. - Significant radiation exposure to staff if safety protocols are breached.

Prior to using Mibg (I123) Curium Netherlands, several safety considerations should be observed.

Pregnancy: avoid unless the diagnostic benefit outweighs fetal radiation risk. Breastfeeding: discontinue nursing for an appropriate period after administration. Renal impairment: assess renal function and consider dose adjustment. Thyroid blocking: administer non‑radioactive iodine to reduce thyroid uptake when indicated. Radiation safety: follow ALARA principles and protect staff and family members. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mibg (I123) Curium Netherlands can interact with other agents that affect catecholamine pathways or radiation exposure.

Major Interactions (Avoid): - Thyroid hormone therapy: may compete with iodine uptake. - Concurrent radiopharmaceuticals: increase cumulative radiation dose. - Sympathomimetic drugs: alter tracer distribution and imaging accuracy.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may reduce NET activity and tracer uptake. - MAO inhibitors: can modify catecholamine metabolism affecting image quality. - Certain chemotherapeutic agents: may interfere with norepinephrine transporter expression.